Patient-Oriented Evidence That Matters

For Three-Vessel Disease, but Not Left Main Disease, CABG Is Preferred over PCI


Am Fam Physician. 2020 Jun 1;101(11):698.

Clinical Question

For patients with three-vessel disease or left main disease, is percutaneous coronary intervention (PCI) with a drug-eluting stent noninferior to coronary artery bypass graft (CABG)?

Bottom Line

For patients with left main disease, PCI with a drug-eluting stent and CABG had similar all-cause mortality rates at 10 years. For those with three-vessel disease, CABG is associated with lower 10-year mortality (21% vs. 28%; number needed to treat = 14). (Level of Evidence = 1b)


This is the 10-year follow-up to a trial that initially randomized 1,800 patients with three-vessel coronary artery disease or left main disease to receive either PCI with a drug-eluting stent or CABG. Groups were balanced at the beginning of the trial, and analysis was by intention to treat. The average age of participants was 65 years, 25% had diabetes mellitus, 33% had a previous myocardial infarction, and 9% had a previous stroke or transient ischemic attack. Left main disease was present in 40% and three-vessel disease in 60% of the patients. The primary outcome was all-cause mortality, ascertained primarily from national death registries. Median follow-up was 11.2 years. At 10 years, 27% of patients in the PCI group had died compared with 24% in the CABG group (hazard ratio = 1.17; 95% CI, 0.97 to 1.41). Analyzing the period from five years to 10 years separately, the authors again found no significant difference (13% for PCI vs. 12% for CABG). There was a difference between groups based on their initial lesion. In those with three-vessel disease, all-cause mortality was significantly higher in the PCI group (28% vs. 21%; hazard ratio = 1.41; 95% CI, 1.10 to 1.80), whereas there was no difference in mortality for those with left main disease (26% for PCI vs. 28% for CABG). Results were similar for patients with and without diabetes.

Study design: Randomized controlled trial (nonblinded)

Funding source: Government

Allocation: Concealed

Setting: Outpatient (any)

Reference: Thuijs DJ,

POEMs (patient-oriented evidence that matters) are provided by Essential Evidence Plus, a point-of-care clinical decision support system published by Wiley-Blackwell. For more information, see http://www.essentialevidenceplus.com. Copyright Wiley-Blackwell. Used with permission.

For definitions of levels of evidence used in POEMs, see http://www.essentialevidenceplus.com/product/ebm_loe.cfm?show=oxford.

To subscribe to a free podcast of these and other POEMs that appear in AFP, search in iTunes for “POEM of the Week” or go to http://goo.gl/3niWXb.

This series is coordinated by Sumi Sexton, MD, editor-in-chief.

A collection of POEMs published in AFP is available at https://www.aafp.org/afp/poems.



Want to use this article elsewhere? Get Permissions

More in AFP

Editor's Collections

Related Content

More in Pubmed


Jan 2022

Access the latest issue of American Family Physician

Read the Issue

Email Alerts

Don't miss a single issue. Sign up for the free AFP email table of contents.

Sign Up Now

Navigate this Article